CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Sunscreen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05736224
NCT05736224Phase 1Completed
CompareCT.gov

Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen

Yale University·interventional·Posted Feb 21, 2023·Updated Nov 27, 2024

In Brief

A Phase 1 clinical trial evaluating Sunscreen and UV Light for Skin Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The primary objective of this study is to evaluate the effects of a novel sunscreen formulation by assessing the extent of ultraviolet radiation (UVR)-induced direct and indirect cellular and DNA damage to human skin, in the presence vs absence of the sunscreen, in a population of healthy adults with fair skin (Fitzpatrick Scale type I, II or III).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
202420252026
First PostedFeb 21, 2023
Enrollment StartMay 15, 2023
Primary CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.4 years ago

Interventions

Sunscreendrug

The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and trans-resveratrol.

UV Lightother

UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.